medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2023, Number 3

<< Back Next >>

Rev Mex Urol 2023; 83 (3)

Clinical evolution of patients with non-muscle invasive bladder cancer treated with bacillus Calmette-Guérin

Caballero-Aguirrechu I, Pomacussi-Villca YL, Zabala-Rodríguez FA, López-Caballero N, Carballo-Torres D, Calzada-Piquera L, Hernández-Castro JL, Roche-Albernas C

Language: Spanish
References: 21
Page: 1-13
PDF size: 284.33 Kb.


ABSTRACT

Introduction: In non-muscle-invasive high-grade carcinoma of the bladder, after resection, intravesical treatment with bacillus Calmette-Guérin is recommended.
Objective: To characterize the patients with CVNMI treated with 40 mg of the bacillus, safety, and recurrence/progression rate pattern.
Methodology: A descriptive study of 77 patients from the Hospital Hermanos Ameijeiras, treated from 2012 to 2016. Cox logistic regression and Kaplan- Meier survival curves were used, with 0,05 significance level (95% confidence interval).
Results and value: The mean age was 70.2 years, 80.5% male and 85.7% smokers. High-grade lesions, bladder lateral site, and smaller than 3 cm predominated (70%). Rate to recurrence/progression of patients was 50.6/39.1 %. Progression-free survival was 4.7 years, significant in those with multiple, high-grade, and T1 lesions (p < 0.05). The main adverse events were cystitis and grade 1-2 fever.
Conclusions: male patients and smokers predominated, as well as smaller and high-grade tumors. The relationship of progression with the presence of high grade, female sex and old age was significant. BCG administration at 40 mg, up to 18 doses was safe and beneficial in overall survival, but not in relapse/ progression-free survival, in relation to the presence of T1, multiple, and high- grade lesions.


REFERENCES

  1. Sung H, Ferlay J, Siegel RL, LaversanneM, Soerjomataram I, Jemal A, et al. GlobalCancer Statistics 2020: GLOBOCAN Estimatesof Incidence and Mortality Worldwide for 36Cancers in 185 Countries. CA: A Cancer Journalfor Clinicians. 2021;71(3):209–49. doi: https://doi.org/10.3322/caac.21660

  2. Saginala K, Barsouk A, Aluru JS, Rawla P,Padala SA, Barsouk A. Epidemiology of BladderCancer. Med Sci (Basel). 2020;8(1):15. doi:https://doi.org/10.3390/medsci8010015

  3. Islami F, Goding Sauer A, Miller KD, SiegelRL, Fedewa SA, Jacobs EJ, et al. Proportion andnumber of cancer cases and deaths attributableto potentially modifiable risk factors in theUnited States. CA Cancer J Clin. 2018;68(1):31–54. https://doi.org/10.3322/caac.21440

  4. Ministerio de Salud Pública. AnuarioEstadístico de Salud 2020. Cuba: Ministerio deSalud Pública; 2020 p. 204. https://salud.msp.gob.cu/wp-content/Anuario/Anuario-2020

  5. European Association of Urology. EAUGuidelines. Annual Congress Milan 2021. TheNetherlands: European Association of Urology;2021. doi: https://www.europeanurology.com

  6. Mugiya S, Nagata M, Takayama T, Ozono S,Ito T, Maruyama S, et al. Intravesical BacillusCalmette-Guerin (BCG: Tokyo 172 strain)instillation for carcinoma in situ of the bladder:results with 6 successive instillations of 40 mgBCG. Hinyokika Kiyo. 2004 Jul;50(7):469-73.https://pubmed.ncbi.nlm.nih.gov/15334890/

  7. Schmidt S, Kunath F, Coles B, Draeger DL,Krabbe L-M, Dersch R, et al. IntravesicalBacillus Calmette-Guérin versus mitomycin Cfor Ta and T1 bladder cancer. Cochrane DatabaseSyst Rev. 2020;1(1):CD011935. doi: https://doi.org/10.1002/14651858.CD011935.pub2

  8. Pramod SV, Safriadi F, Hernowo BS, DwiyanaRF, Batista B. Smoking history, smokingintensity, and type of cigarette as risk factors ofbladder cancer: A literature review. UrologicalScience. 2020;31(4):147. doi: https://doi.org/10.4103/uros.uros_6_20

  9. Mateu L, García-Cruz E, Asiaín I, CastañedaR, Carrión A, Huguet J, et al. Un mayor índicede comorbilidad de Charlson se relacionacon características más agresivas de lostumores vesicales de novo. Actas UrológicasEspañolas. 2016;40(1):23–8. doi: https://doi.org/10.1016/j.acuro.2015.06.006

  10. Rivera MA. Caracterización clínica,epidemiológica y anatomopatológica de lospacientes con cáncer de vejiga. Revista Cubanade Urología. 2018;7(0):45. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=87904

  11. Liu Y, Lu J, Huang Y, Ma L. Clinical Spectrumof Complications Induced by IntravesicalImmunotherapy of Bacillus Calmette-Guérinfor Bladder Cancer. Journal of Oncology.2019;2019:e6230409. doi:https://doi.org/10.1155/2019/6230409

  12. Rodríguez AM, Vaillant S, Moya C, AcostaM, Fajardo J. Correspondencia ecográfica ytomográfica en el diagnóstico de cáncer de vejiga.MediSan. 2020;24(05):861–74. https://www.redalyc.org/articulo.oa?id=368464850008

  13. Citarella D, Quiroga Matamoros W, FernandezF, Patiño I, Estrada A. Guía de manejo en cáncervesical. Urología Colombiana. 2016;25(2):154–68.doi: https://doi.org/10.1016/j.uroco.2016.03.001

  14. Kamat AM, Gontero P, Palou J. How ShouldI Manage a Patient with Tumor RecurrenceDespite Adequate Bacille Calmette-Guérin?European Urology Oncology. 2020;3(2):252–7.doi: https://doi.org/10.1016/j.euo.2019.06.013

  15. Martin-Doyle W, Leow JJ, Orsola A, ChangSL, Bellmunt J. Improving Selection Criteriafor Early Cystectomy in High-Grade T1 BladderCancer: A Meta-Analysis of 15,215 Patients.JCO. 2015 Feb 20;33(6):643–50. doi: https://doi.org/10.1200/jco.2014.57.6967

  16. Soukup V, Čapoun O, Cohen D, HernándezV, Babjuk M, Burger M, et al. PrognosticPerformance and Reproducibility of the 1973and 2004/2016 World Health OrganizationGrading Classification Systems in Non–muscle-invasive Bladder Cancer: A EuropeanAssociation of Urology Non-muscle InvasiveBladder Cancer Guidelines Panel SystematicReview. European Urology. 2017;72(5):801–13.https://doi.org/10.1016/j.eururo.2017.04.015

  17. Cambier S, Sylvester RJ, Collette L, GonteroP, Brausi MA, van Andel G, et al. EORTCNomograms and Risk Groups for PredictingRecurrence, Progression, and Disease-specificand Overall Survival in Non–Muscle-invasiveStage Ta–T1 Urothelial Bladder Cancer PatientsTreated with 1–3 Years of MaintenanceBacillus Calmette-Guérin. EuropeanUrology. 2016;69(1):60–9. doi: https://doi.org/10.1016/j.eururo.2015.06.045

  18. Lenis AT, Lec PM, Chamie K, MSHS M. BladderCancer: A Review. JAMA. 2020;324(19):1980–91.doi: https://doi.org/10.1001/jama.2020.17598

  19. Millán-Rodríguez F, Chéchile-Toniolo G,Salvador-Bayarri J, Palou J, Algaba F, & Vicente-Rodríguez J. Primary superficial bladder cancerrisk groups according to progression, mortalityand recurrence. The Journal of urology, 2020;164(3 Pt 1): 680–684. https://doi.org/10.1016/s0022-5347(05)67280-1

  20. Sylvester RJ, Van der Meijden AP, OosterlinckW, et al. Predicting recurrence and progressionin individual patients with stage Ta T1 bladdercancer using EORTC risk tables: a combinedanalysis of 2596 patients from seven EORTCtrials. Eur Urol. 2006;49(3):466-477. https://doi:10.1016/j.eururo.2005.12.031

  21. Del Giudice F, Busetto GM, Gross MS, et al.Efficacy of three BCG strains (Connaught, TICEand RIVM) with or without secondary resection(re-TUR) for intermediate/high-risk nonmuscle-invasive bladder cancers: results from aretrospective single-institution cohort analysis. JCancer Res Clin Oncol. 2021;147(10):3073-3080. https://doi:10.1007/s00432-021-03571




2020     |     www.medigraphic.com